Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in …
Background: Tumor immune markers such as tumor infiltrating lymphocytes (TILs) or
expression-based profiles have been correlated with both response to neoadjuvant …
expression-based profiles have been correlated with both response to neoadjuvant …
[HTML][HTML] The tumor and microenvironment crosstalk in breast cancer: from biology to therapeutic opportunity
M Truffi, S Mazzucchelli, II Skvortsova - Frontiers in Oncology, 2024 - frontiersin.org
Breast cancer (BC) is a complex process controlled and coordinated by the crosstalk
between tumor cells and the several components of the tumor microenvironment (TME) …
between tumor cells and the several components of the tumor microenvironment (TME) …
Comprehensive immune profiling unravels evolution of spatial distribution and immune repertoire in tumor microenvironment from primary to metastatic triple-negative …
W Guo, CA Egelston, KE Hutchinson, JM Giltnane… - 2022 - ascopubs.org
1079 Background: Immune checkpoint inhibitors (ICI) have improved PFS and OS in
metastatic triple-negative breast cancer (mTNBC), but benefit is limited to PD-L1 positive …
metastatic triple-negative breast cancer (mTNBC), but benefit is limited to PD-L1 positive …
[HTML][HTML] Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy
G Yin, L Liu, T Yu, L Yu, M Feng, C Zhou, X Wang… - Genome Medicine, 2024 - Springer
Background Neoadjuvant chemotherapy (NAC) has become a standard treatment strategy
for breast cancer (BC). However, owing to the high heterogeneity of these tumors, it is …
for breast cancer (BC). However, owing to the high heterogeneity of these tumors, it is …
Abstract PD5-07: The immune landscape of residual triple-negative breast cancers after neoadjuvant chemotherapy
PI Gonzalez-Ericsson, V Sanchez, R Salgado… - Cancer Research, 2020 - AACR
Background: Although neoadjuvant chemotherapy (NAC) induces complete response in 30-
40% of triple-negative breast cancers (TNBC), patients with residual disease at surgery have …
40% of triple-negative breast cancers (TNBC), patients with residual disease at surgery have …
Measuring the composition of the tumor microenvironment with transcriptome analysis: past, present and future
Interactions between tumor cells and immune cells in the tumor microenvironment (TME)
play a vital role the mechanisms of immune evasion, by which cancer cells escape immune …
play a vital role the mechanisms of immune evasion, by which cancer cells escape immune …
[HTML][HTML] A Retrospective View of the Triple-Negative Breast Cancer Microenvironment: Novel Markers, Interactions, and Mechanisms of Tumor-Associated …
M Kim, W Yang, D Hong, HS Won, S Yoon - Cancers, 2024 - mdpi.com
Simple Summary Triple-negative breast cancer (TNBC) comprises about 15% of all breast
cancers worldwide and is known to have a poorer prognosis compared to other subtypes of …
cancers worldwide and is known to have a poorer prognosis compared to other subtypes of …
Abstract A69: The immunological environment in triple negative breast cancer; impact on clinical outcomes towards a prognostic clinical test
It is now accepted that changes in the normal cells that constitute the tumor
microenvironment (TME) play important roles in determining cancer progression and …
microenvironment (TME) play important roles in determining cancer progression and …
[HTML][HTML] A high-dimensional window into the micro-environment of triple negative breast cancer
Simple Summary Triple negative breast cancer (TNBC) shows a substantial level of
genomic, cellular, and phenotypic heterogeneity. While genomic heterogeneity and …
genomic, cellular, and phenotypic heterogeneity. While genomic heterogeneity and …
Abstract P3-08-15: Immunologic correlates of long-term outcome in the residual disease of triple-negative breast cancer after neoadjuvant chemotherapy
The recent approval of anti-PD-L1 immunotherapy in combination with nAB-paclitaxel for
metastatic triple-negative breast cancer (TNBC) highlights the need to understand the role of …
metastatic triple-negative breast cancer (TNBC) highlights the need to understand the role of …